The DOI matches its Crossref record; 114 of the 115 references it cites were found in a registry or an index.
Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's Diseases
Open accessAbstract
BACKGROUND: Misfolding and pathological aggregation of neuronal proteins has been proposed to play a critical role in the pathogenesis of neurodegenerative disorders. Alzheimer's disease (AD) and Parkinson's disease (PD) are frequent neurodegenerative diseases of the aging population. While progressive accumulation of amyloid beta protein (Abeta) oligomers has been identified as one of the central toxic events in AD, accumulation of alpha-synuclein (alpha-syn) resulting in the formation of oligomers and protofibrils has been linked to PD and Lewy body Disease (LBD). We have recently shown that Abeta promotes alpha-syn aggregation and toxic conversion in vivo, suggesting that abnormal interactions between misfolded proteins might contribute to disease pathogenesis. However the molecular characteristics and consequences of these interactions are not completely clear. METHODOLOGY/PRINCIPAL FINDINGS: In order to understand the molecular mechanisms involved in potential Abeta/alpha-syn interactions, immunoblot, molecular modeling, and in vitro studies with alpha-syn and Abeta were performed. We showed in vivo in the brains of patients with AD/PD and in transgenic mice, Abeta and alpha-synuclein co-immunoprecipitate and form complexes. Molecular modeling and simulations showed that Abeta binds alpha-syn monomers, homodimers, and trimers, forming hybrid ring-like pentamers. Interactions occurred between the N-terminus of Abeta and the N-terminus and C-terminus of alpha-syn. Interacting alpha-syn and Abeta dimers that dock on the membrane incorporated additional alpha-syn molecules, leading to the formation of more stable pentamers and hexamers that adopt a ring-like structure. Consistent with the simulations, under in vitro cell-free conditions, Abeta interacted with alpha-syn, forming hybrid pore-like oligomers. Moreover, cells expressing alpha-syn and treated with Abeta displayed increased current amplitudes and calcium influx consistent with the formation of cation channels. CONCLUSION/SIGNIFICANCE: These results support the contention that Abeta directly interacts with alpha-syn and stabilized the formation of hybrid nanopores that alter neuronal activity and might contribute to the mechanisms of neurodegeneration in AD and PD. The broader implications of such hybrid interactions might be important to the pathogenesis of other disorders of protein misfolding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Co-immunoprecipitation experiments have shown that αSyn monomers, dimers, trimers and pentamers bind to monomeric Aβ in post-mortem samples from AD and DLB brains [67].”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [67]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A smooth particle mesh Ewald method
Essmann, U., Perera, L., Berkowitz, M., Darden, T., Lee, H.-C., & Pedersen, L. (1995) · The Journal of Chemical Physics · doi:10.1063/1.470117 · Cited by 21,378
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Lipid rafts and signal transduction
Simons, K., & Toomre, D. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35036052 · Cited by 5,371
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Constant pressure molecular dynamics simulation: The Langevin piston method
Feller, S., Zhang, Y., Pastor, R., & Brooks, B. (1995) · The Journal of Chemical Physics · doi:10.1063/1.470648 · Cited by 4,271
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
Reversible multiple time scale molecular dynamics
Tuckerman, M. E., Berne, B. J., & Martyna, G. J. (1992) · The Journal of Chemical Physics · doi:10.1063/1.463137 · Cited by 3,623
NAMD2: Greater Scalability for Parallel Molecular Dynamics
Kalé, L. V., Skeel, R. D., Bhandarkar, M. A., Brunner, R., Gürsoy, A., Krawetz, N., Phillips, J., Shinozaki, A., Varadarajan, K., & Schulten, K. J. (1999) · Journal of Computational Physics · doi:10.1006/jcph.1999.6201 · Cited by 2,428
Masliah, E., Rockenstein, E. M., Veinbergs, I., Mallory, M. E., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,779
Self-citationCaughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650
Flagged first, then by citations
1 of the 115 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- IG McKeith, 1996, Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop., Neurology, 47, 1113, 10.1212/WNL.47.5.1113 · DOI · Paper page
Cited by
Sorted by citations
Items 101–200 of 281
Progress of immunotherapy of anti-α-synuclein in Parkinson’s disease
Wang, Z., Gao, G., Duan, C., & Yang, H. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108843 · Cited by 62
AD synapses contain abundant Aβ monomer and multiple soluble oligomers, including a 56-kDa assembly
Sokolow, S., Henkins, K. M., Bilousova, T. V., Miller, C. A., Vinters, H. V., Poon, W. W., Cole, G. M., & Gylys, K. H. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.011 · Cited by 61
Young, L. M., Mahood, R. A., Saunders, J. C., Tu, L., Raleigh, D. P., Radford, S. E., & Ashcroft, A. E. (2015) · The Analyst · doi:10.1039/c5an00865d · Cited by 57
α-synuclein induced synapse damage is enhanced by amyloid-β1-42
Bate, C., Gentleman, S., & Williams, A. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-55 · Cited by 55
Intermediates of α-synuclein aggregation: Implications in Parkinson's disease pathogenesis
Gadhe, L. G., Sakunthala, A., Mukherjee, S., Gahlot, N., Bera, R., Sawner, A. S., Kadu, P., & Maji, S. K. (2021) · Biophysical Chemistry · doi:10.1016/j.bpc.2021.106736 · Cited by 56
α-Synuclein Aggregation Is Triggered by Oligomeric Amyloid-β 42 via Heterogeneous Primary Nucleation
Vadukul, D. M., Papp, M., Thrush, R. J., Wang, J., Jin, Y., Arosio, P., & Aprile, F. A. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c03212 · Cited by 55
Protein–protein interactions regulating α-synuclein pathology
Wang, J., Dai, L., Chen, S., Zhang, Z., Fang, X., & Zhang, Z. (2024) · Trends in Neurosciences · doi:10.1016/j.tins.2024.01.002 · Cited by 58
Spencer, B. J., Desplats, P., Overk, C., Valera, E., Rissman, R. A., Wu, C., Mante, M., Adame, A., Florio, J. B., Rockenstein, E. M., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0775-16.2016 · Cited by 56
Self-citationEffects of saffron and its constituents, crocin-1, crocin-2, and crocetin on α-synuclein fibrils
Inoue, E., Shimizu, Y., Masui, R., Hayakawa, T., Tsubonoya, T., Hori, S., & Sudoh, K. (2017) · Journal of Natural Medicines · doi:10.1007/s11418-017-1150-1 · Cited by 47
Pathogenic Mutations Differentially Regulate Cell-to-Cell Transmission of α-Synuclein
Guan, Y., Zhao, X., Liu, F., Yan, S., Wang, Y., Du, C., Cui, X., Li, R., & Zhang, C. X. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00159 · Cited by 54
α-Synuclein increases β-amyloid secretion by promoting β-/γ-secretase processing of APP
Hall‐Roberts, H., Schneider, B. L., & Brown, D. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171925 · Cited by 55
New ¿- and ¿-synuclein immunopathological lesions in human brain
Surgucheva, I. G., Newell, K. L., Burns, J. M., & Surguchov, A. P. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0132-8 · Cited by 57
Atsmon‐Raz, Y., & Miller, Y. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00204 · Cited by 56
Moda, F., Ciullini, A., Dellarole, I. L., Lombardo, A., Campanella, N., Bufano, G., Cazzaniga, F. A., & Giaccone, G. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2810255 · Cited by 49
PESCADOR, a web-based tool to assist text-mining of biointeractions extracted from PubMed queries
Barbosa-Silva, A., Fontaine, J., Donnard, E. R., Stussi, F., Ortega, J. M., & Andrade-Navarro, M. A. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-435 · Cited by 51
Pacheco, C., Aguayo, L. G., & Opazo, C. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00297 · Cited by 52
The amyloid interactome: Exploring protein aggregation
Biza, K. V., Nastou, K. C., Tsiolaki, P. L., Mastrokalou, C. V., Hamodrakas, S. J., & Iconomidou, V. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173163 · Cited by 48
Quantifying Co-Oligomer Formation by α-Synuclein
Iljina, M., Dear, A. J., Garcia, G. A., De, S., Tosatto, L., Flagmeier, P., Whiten, D. R., Michaels, T. C. T., Frenkel, D., Dobson, C. M., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b03575 · Cited by 51
Protein Co-Aggregation Related to Amyloids: Methods of Investigation, Diversity, and Classification
Bondarev, S. A., Antonets, K. S., Kajava, A. V., Nizhnikov, A. A., & Zhouravleva, G. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082292 · Cited by 49
Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers
Kreiser, R. P., Wright, A. K., Block, N. R., Hollows, J. E., Nguyen, L. T., LeForte, K., Mannini, B., Vendruscolo, M., & Limbocker, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228651 · Cited by 48
Synucleins: Are they two‐edged swords?
Surguchov, A. P. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23149 · Cited by 46
Molecular Determinants of α-Synuclein Mutants’ Oligomerization and Membrane Interactions
Tsigelny, I. F., Sharikov, Y., Kouznetsova, V. L., Greenberg, J. P., Wrasidlo, W., Overk, C., Gonzalez, T., Trejo, M., Spencer, B. J., Kosberg, K. A., et al. (2015) · ACS Chemical Neuroscience · doi:10.1021/cn500332w · Cited by 45
Self-citationAssessing the causes and consequences of co-polymerization in amyloid formation
Sarell, C. J., Stockley, P. G., & Radford, S. E. (2013) · Prion · doi:10.4161/pri.26415 · Cited by 44
Copper(I/II), α/β‐Synuclein and Amyloid‐β: Menage à Trois?
Ricco, R. D., Valensin, D., Dell’Acqua, S., Casella, L., Hureau, C., & Faller, P. (2015) · ChemBioChem · doi:10.1002/cbic.201500425 · Cited by 46
Limegrover, C. S., Yurko, R., Izzo, N. J., LaBarbera, K. M., Rehak, C., Look, G., Rishton, G., Safferstein, H., & Catalano, S. M. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24782 · Cited by 43
Spencer, B. J., Williams, S. M., Rockenstein, E. M., Valera, E., Xin, W., Mante, M., Florio, J. B., Adame, A., Masliah, E., & Sierks, M. R. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.321 · Cited by 43
Self-citationRetractedAssociation of HLA-DRB1 polymorphism with Alzheimer's disease: a replication and meta-analysis
Lu, R.-C., Yang, W., Tan, L., Sun, F.-R., Tan, M.-S., Zhang, W., Wang, H.-F., & Tan, L. (2017) · Oncotarget · doi:10.18632/oncotarget.21479 · Cited by 43
Tosun, D., Hausle, Z., Thropp, P., Concha‐Marambio, L., Lamoureux, J., Lebovitz, R. M., Shaw, L. M. J., Singleton, A., Weiner, M. W., Initiative, T. A. D. N., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14276 · Cited by 42
Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers
Aasly, J. O., Shi, M. Y., Sossi, V., Stewart, T., Johansen, K. K., Wszołek, Z. K., Uitti, R. J., Hasegawa, K., Yokoyama, T., Zabetian, C. P., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31823ed101 · Cited by 42
Aβ Seeding as a Tool to Study Cerebral Amyloidosis and Associated Pathology
Friesen, M., & Meyer‐Luehmann, M. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00233 · Cited by 41
Mechanistic Insights into the Co-Aggregation of Aβ and hIAPP: An All-Atom Molecular Dynamic Study
Li, X., Lao, Z., Zou, Y. F., Dong, X., Li, L., & Wei, G. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c11132 · Cited by 42
Prion Strain Interactions Are Highly Selective
Nilsson, K. P. R., Joshi-Barr, S., Winson, O., & Sigurdson, C. J. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.2417-10.2010 · Cited by 41
Leukotrienes vs. Montelukast—Activity, Metabolism, and Toxicity Hints for Repurposing
Marques, C. F., Marques, M. M., & Justino, G. C. (2022) · Pharmaceuticals · doi:10.3390/ph15091039 · Cited by 47
Kravenska, Y., Nieznańska, H., Nieznański, K., Lukyanetz, E. A., Szewczyk, A. M., & Koprowski, P. (2020) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2020.183337 · Cited by 39
Sang, C., Philbert, S. A., Hartland, D., Unwin, R. D., Dowsey, A. W., Xu, J., & Cooper, G. J. S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.893159 · Cited by 40
Elevated mRNA Expression and Low Methylation of SNCA in Japanese Alzheimer’s Disease Subjects
Yoshino, Y., Mori, T., Yoshida, T., Yamazaki, K., Ozaki, Y., Sao, T., Funahashi, Y., Iga, J., & Ueno, S. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160430 · Cited by 40
Daniele, S., Pietrobono, D., Fusi, J., Iofrida, C., Chico, L., Petrozzi, L., Gerfo, A. L., Baldacci, F., Galetta, F., Siciliano, G., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0523-5 · Cited by 41
Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias
Bohnen, N. I., Müller, M. L. T. M., & Frey, K. A. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0789-z · Cited by 39
CSF beta‐amyloid 1–42 – what are we measuring in Alzheimer's disease?
Hu, W. T., Watts, K. D., Shaw, L. M. J., Howell, J. C., Trojanowski, J. Q., Basra, S. S., Glass, J. D., Lah, J. J., & Levey, A. I. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.160 · Cited by 38
Candreva, J., Chau, E., Rice, M. E., & Kim, J. R. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00655 · Cited by 39
In Vivo Alterations in Calcium Buffering Capacity in Transgenic Mouse Model of Synucleinopathy
Reznichenko, L., Cheng, Q., Nizar, K., Gratiy, S. L., Saisan, P. A., Rockenstein, E. M., Gonzalez, T., Patrick, C., Spencer, B. J., Desplats, P., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1270-12.2012 · Cited by 37
Self-citationDopamine‐induced α‐synuclein oligomers show self‐ and cross‐propagation properties
Planchard, M. S., Exley, S. E., Morgan, S. E., & Rangachari, V. (2014) · Protein Science · doi:10.1002/pro.2521 · Cited by 35
Mougenot, A.-L. J., Bencsik, A. A., Nicot, S., Vulin, J., Morignat, E., Verchère, J., Bétemps, D., Lakhdar, L., Legastelois, S., & Baron, T. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318217d95f · Cited by 36
Fortuna, J. T. S., Gralle, M., Beckman, D., Neves, F., Diniz, L. P., Frost, P. S., Barros‐Aragão, F. G. Q., Santos, L. E., Gonçalves, R. A., Romão, L. F., et al. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.06.047 · Cited by 34
Wang, H., Stewart, T., Toledo, J. B., Ginghina, C., Tang, L., Atik, A., Aro, P., Shaw, L. M., Trojanowski, J. Q., Galasko, D. R., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171013 · Cited by 33
Tsigelny, I. F., Sharikov, Y., Kouznetsova, V. L., Greenberg, J. P., Wrasidlo, W., Gonzalez, T., Desplats, P., Michael, S. E., Trejo, M., Overk, C., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131589 · Cited by 33
Self-citationJose, J. C., Chatterjee, P., & Sengupta, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106883 · Cited by 32
A SUMO1-Derived Peptide Targeting SUMO-Interacting Motif Inhibits α-Synuclein Aggregation
Liang, Z., Chan, H. Y. E., Lee, M. M., & Chan, M. K. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2020.12.010 · Cited by 31
Association of HLA-DR/DQ Polymorphism With Alzheimer’s Disease
Mansouri, L., Klai, S., Gritli, N., Fekih‐Mrissa, N., Messelmani, M., Bedoui, I., Derbali, H., & Mrissa, R. (2015) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000416 · Cited by 31
Wang, X., Li, H., Sheng, Y., He, B., Liu, Z., Li, W., Yu, S., Wang, J., Zhang, Y., Chen, J., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116071 · Cited by 29
Interaction of LRRK2 and α-Synuclein in Parkinson’s Disease
Daher, J. P. L. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-49969-7_11 · Cited by 30
α-Synuclein Aggregation and Modulating Factors
Paleologou, K. E., & El‐Agnaf, O. M. A. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-5416-4_6 · Cited by 33
Mandler, M., Rockenstein, E. M., Overk, C., Mante, M., Florio, J. B., Adame, A., Kim, C., Santic, R., Schneeberger, A., Mattner, F., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.02.002 · Cited by 29
Self-citationRajendran, R., Raghavan, R. P., Al-Sehemi, A. G., Uddin, M. S., Aleya, L., & Mathew, B. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-17931-3 · Cited by 29
Daniele, S., Pietrobono, D., Fusi, J., Gerfo, A. L., Cerri, E., Chico, L., Iofrida, C., Petrozzi, L., Baldacci, F., Giacomelli, C., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00017 · Cited by 28
Role of cellular prion protein in interneuronal amyloid transmission
del Rı́o, J. A., Ferrer, I., & Gavı́n, R. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.03.001 · Cited by 30
α-synuclein-assisted oligomerization of β-amyloid (1–42)
Chau, E., & Kim, J. R. (2022) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2022.109120 · Cited by 30
Interactions of amyloid coaggregates with biomolecules and its relevance to neurodegeneration
Murakami, K., & Ono, K. (2022) · The FASEB Journal · doi:10.1096/fj.202200235r · Cited by 28
Is the p3 Peptide (Aβ17-40, Aβ17-42) Relevant to the Pathology of Alzheimer’s Disease?1
Kuhn, A. J., & Raskatov, J. A. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191201 · Cited by 31
Physical and toxicological profiles of human IAPP amyloids and plaques
Käkinen, A., Sun, Y., Javed, I., Faridi, A., Pilkington, E. H., Faridi, P., Purcell, A. W., Zhou, R., Ding, F., Lin, S., et al. (2018) · 中国科学通报：英文版 · doi:10.1016/j.scib.2018.11.012 · Cited by 27
Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model
Lloyd, G. M., Dhillon, J.-K. S., Gorion, K.-M. M., Riffe, C. J., Fromholt, S., Xia, Y., Giasson, B. I., & Borchelt, D. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00486-9 · Cited by 29
Arya, S., Claud, S. L., Cantrell, K. L., & Bowers, M. T. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00516 · Cited by 27
Uncovering the Binding and Specificity of β-Wrapins for Amyloid-β and α-Synuclein
Orr, A. A., Wördehoff, M. M., Hoyer, W., & Tamamis, P. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b08485 · Cited by 26
β-Amyloid and α-Synuclein Cooperate To Block SNARE-Dependent Vesicle Fusion
Choi, B.-K., Kim, J.-Y., Cha, M.-Y., Mook‐Jung, I., Shin, Y.-K., & Lee, N. K. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00087 · Cited by 27
RetractedHuang, X., Wang, C., Chen, L., Zhang, T., Leung, K. L., & Wong, G. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166203 · Cited by 26
Noguchi‐Shinohara, M., & Ono, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210215 · Cited by 24
Huang, F., Liu, Y., Wang, Y., Xu, J., Lian, J., Zou, Y. F., Wang, C., Ding, F., & Sun, Y. (2023) · Physical Chemistry Chemical Physics · doi:10.1039/d3cp04138g · Cited by 24
Masliah, E., Rockenstein, E. M., Inglis, C. A., Adame, A., Bett, C. K., Lucero, M., & Sigurdson, C. J. (2012) · Prion · doi:10.4161/pri.19806 · Cited by 26
Self-citationWilliams, S. M., Schulz, P., Rosenberry, T. L., Caselli, R. J., & Sierks, M. R. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161116 · Cited by 24
Parkinson’s Disease: A Prionopathy?
Vascellari, S., & Manzin, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158022 · Cited by 26
Profiling of Alzheimer’s disease related genes in mild to moderate vitamin D hypovitaminosis
Grimm, M. O. W., Lauer, A. A., Grösgen, S., Thiel, A., Lehmann, J., Winkler, J., Janitschke, D., Herr, C., Beißwenger, C., Bals, R., et al. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.01.015 · Cited by 22
Amyloid Protein Cross-Seeding Provides a New Perspective on Multiple Diseases In Vivo
Ge, W., Deng, X., Shi, W., Lin, W.-J., Chen, L., Liang, H., Wang, X., Zhang, T., Zhao, F., Guo, W., et al. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.2c01233 · Cited by 24
Oláh, J., Bertrand, P., & Ovádi, J. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1304216 · Cited by 20
Inhibition of Aβ42 oligomerization in yeast by a PICALM ortholog and certain FDA approved drugs
Park, S.-K., Ratia, K. M., Ba, M. A., Valencik, M. L., & Liebman, S. W. (2016) · Microbial Cell · doi:10.15698/mic2016.02.476 · Cited by 21
α-Synuclein binds to cytoplasmic vesicles in U251 glioblastoma cells
Duan, J., Ying, Z., Su, Y., Lin, F., & Deng, Y. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.01.067 · Cited by 19
Almansoub, H. A. M. M., Tang, H. R., Wu, Y., Wang, D., Mahaman, Y. A. R., Salissou, M. T. M., Lu, Y., Hu, F., Zhou, L., Almansob, Y. A. M., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191091 · Cited by 20
CSF α-synuclein, tau, and amyloid β in Parkinson's disease
Shi, M. Y., & Zhang, J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70130-2 · Cited by 18
α‐Synuclein Oligomers: A Study in Diversity
van Diggelen, F., Tepper, A. W. J. W., Apetri, M. M., & Otzen, D. E. (2016) · Israel Journal of Chemistry · doi:10.1002/ijch.201600116 · Cited by 18
Formation of Heterotypic Amyloids: α‐Synuclein in Co‐Aggregation
Bhasne, K., & Mukhopadhyay, S. (2018) · PROTEOMICS · doi:10.1002/pmic.201800059 · Cited by 17
Lin, S., Leitao, A. D. G., Fang, S., Gu, Y., Barber, S., Gilliard-Telefoni, R., Castro, A., Sung, K., Shen, R., Florio, J. B., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106010 · Cited by 17
Self-citationConcomitant protein pathogenesis in Parkinson’s disease and perspective mechanisms
Han, Y., & He, Z. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1189809 · Cited by 18
Interaction of Proteins Involved in Neuronal Proteinopathies
Kulichikhin, K. Y., Malikova, O. A., Zobnina, A. E., Zalutskaya, N. M., & Rubel, A. A. (2023) · Life · doi:10.3390/life13101954 · Cited by 17
Preparation of α-Synuclein Amyloid Assemblies for Toxicity Experiments
Chen, S. W., & Cremades, N. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7816-8_4 · Cited by 16
SRCP1 Conveys Resistance to Polyglutamine Aggregation
Santarriaga, S., Haver, H. N., Kanack, A. J., Fikejs, A. S., Sison, S. L., Egner, J. M., Bostrom, J. R., Seminary, E. R., Hill, R. B., Link, B. A., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.008 · Cited by 15
Liu, Y., Koyutürk, M., Maxwell, S., Zhao, Z., & Chance, M. R. (2012) · Europe PMC (PubMed Central) · Cited by 16
Maingi, V., Zhang, Z., Thachuk, C., Sarraf, N., Chapman, E. R., & Rothemund, P. W. K. (2023) · Nature Communications · doi:10.1038/s41467-023-36996-x · Cited by 15
Li, X., Zhang, Y., Yang, Z., Zhang, S., & Zhang, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031636 · Cited by 16
Mechanisms of Transthyretin Aggregation and Toxicity
Gasperini, R., Klaver, D. W., Hou, X., Aguilar, M., & Small, D. H. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-5416-4_9 · Cited by 14
Abdullah, R., Patil, K. S., Rosen, B., Pal, R., Prabhudesai, S. N., Lee, S., Basak, I., Hoedt, E., Yang, P. H., Panick, K., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0266-8 · Cited by 14
Davtyan, H., Zagorski, K., Petrushina, I., Kazarian, K., Goldberg, N. R. S., Petrosyan, J., Blurton-Jones, M. M., Masliah, E., Cribbs, D. H., Agadjanyan, M. G., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.08.006 · Cited by 15
Self-citationFunctional Amyloids and their Possible Influence on Alzheimer Disease
Lau, A., Bourkas, M. E. C., Lu, Y. Q. Q., Ostrowski, L., Weber‐Adrian, D., Figueiredo, C., Arshad, H., Shoaei, S. Z. S., Morrone, C. D., Matan‐Lithwick, S. A., et al. (2017) · Discoveries · doi:10.15190/d.2017.9 · Cited by 13
Lee, J. E., Cho, K. H., Kim, M., Sohn, Y. H., & Lee, P. H. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6203-x · Cited by 13
Oligomerization by co-assembly of β-amyloid and α-synuclein
Kim, J. R. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1153839 · Cited by 13
Chiliveri, S. C., Shen, Y., Baber, J. L., Ying, J., Sagar, V., Wistow, G. J., Anfinrud, P., & Bax, A. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c05710 · Cited by 13
Randhawa, S., Dar, A. I., Saini, T. C., Bathla, M., & Acharya, A. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102243 · Cited by 12
Multiple system atrophy with amyloid-β-predominant Alzheimer’s disease neuropathologic change
Kon, T., Ichimata, S., Luca, D. G. D., Martínez-Valbuena, I., Kim, A., Yoshida, K., Alruwaita, A. A., Kleiner, G., Strafella, A. P., Forrest, S. L., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae141 · Cited by 13
α-synuclein as an emerging pathophysiological biomarker of Alzheimer’s disease
Beatino, M. F., Luca, C. D., Campese, N., Belli, E., Piccarducci, R., Giampietri, L., Martini, C., Perugi, G., Siciliano, G., Ceravolo, R., et al. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2068952 · Cited by 11
Toxicity of serum albumin on microglia upon seeding effect of amyloid peptide
Ferdousi, M., Habibi-Rezaei, M., Balalaie, S., Ramezanpour, S., Sabouni, F., Poursasan, N., Sabokdast, M., & Moosavi‐Movahedi, A. A. (2016) · The Journal of Biochemistry · doi:10.1093/jb/mvw042 · Cited by 11
Borro, B. C., Parolini, L., Cicuta, P., Foderà, V., & Michele, L. D. (2017) · Physical Chemistry Chemical Physics · doi:10.1039/c7cp05339h · Cited by 11
Ma, K., Song, L.-K., Long, W. A., Yuan, Y., Zhang, Y., Song, X., Niu, F., Han, N., & Chen, N. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2012.10.007 · Cited by 11
Metadata
- Authors
- Tsigelny, I. F., Crews, L., Desplats, P., Shaked, G. M., Sharikov, Y., Mizuno, H., Spencer, B., Rockenstein, E., Trejo, M., Platoshyn, O., Yuan, J. X.-J., & Masliah, E.
- Affiliations
- San Diego Supercomputer Center (US)
- University of California San Diego (US)
- Corresponding author
- Masliah, Eliezer
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-09-04
- Volume
- 3
- Issue
- 9
- Pages
- e3135
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2519786
- OpenAlex
- W2065878937
- Cited by
- 281
- References
- 115
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 14 · 2023: 14 · 2022: 13 · 2021: 18 · 2020: 25 · 2019: 20 · 2018: 18 · 2017: 22 · 2016: 16 · 2015: 18 · 2014: 14 · 2013: 9 · 2012: 21
- FWCI
- 9.93
- Type
- journal article
- Language
- en
- Status
- Retracted
- Update notices
- retraction (2025-03-18)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- U.S. Department of Energy
- National Institutes of Health (AG‐18440)
- National Institute on Aging (R37AG018440, R01AG018440, AG 18440)
- National Heart, Lung, and Blood Institute (R01HL066012, HL066012)
- Argonne National Laboratory
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, Parkinson's disease, amyloid-beta, alpha-synuclein, protein-protein interaction, protein misfolding, Lewy body disease, nanopores, cation channels, calcium influx, protein aggregation, transgenic mice
- MeSH terms
- Alzheimer Disease, Animals, Brain, Calcium, Computer Simulation, Electrophysiology, Humans, Mice, Transgenic, Parkinson Disease, Protein Denaturation, Protein Structure, Tertiary, Protein Folding, Lewy Body Disease, Mice, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
